Who's a Good Candidate for HRT — and Who Isn't

What makes someone a good candidate for HRT?

A good candidate for systemic hormone therapy is often a healthy woman under 60 or within 10 years of her final period who has bothersome symptoms. According to The North American Menopause Society, this group generally sees benefits that outweigh the risks for relief of hot flashes and night sweats 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.2022 NAMS position statement: good candidates are typically healthy women under 60 or within 10 years of menopause; contraindications include estrogen-sensitive cancers, clots, stroke, heart attack, unexplained bleeding, and active liver disease; transdermal routes lower clot risk; duration is individualized with no single mandatory stopping point.. Bothersome menopause symptoms, rather than menopause alone, are the usual reason to consider it, since about 3 in 4 women have vasomotor symptoms 2Ref 2American College of Obstetricians and Gynecologists (2014).ACOG Practice Bulletin No. 141: management of menopausal symptoms.ACOG Practice Bulletin 141: about three in four women experience vasomotor symptoms during the menopause transition.. Candidacy also shifts by life stage: women with early menopause or primary ovarian insufficiency, before about age 40, are often advised estrogen until the usual menopause age 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.2022 NAMS position statement: good candidates are typically healthy women under 60 or within 10 years of menopause; contraindications include estrogen-sensitive cancers, clots, stroke, heart attack, unexplained bleeding, and active liver disease; transdermal routes lower clot risk; duration is individualized with no single mandatory stopping point.. Age, timing, symptom burden, and health history all feed the decision, which is why two women the same age can get different advice.

Why does timing matter so much?

Timing matters because the same therapy carries a different risk balance depending on how long ago menopause occurred. The timing hypothesis holds that starting near menopause is safer for the heart and blood vessels than starting many years later 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.2022 NAMS position statement: good candidates are typically healthy women under 60 or within 10 years of menopause; contraindications include estrogen-sensitive cancers, clots, stroke, heart attack, unexplained bleeding, and active liver disease; transdermal routes lower clot risk; duration is individualized with no single mandatory stopping point.. In the KEEPS trial, recently menopausal women showed no harmful effect on early markers of artery disease over 4 years 3Ref 3Harman SM, Black DM, Naftolin F, et al. (2014).Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial.KEEPS trial: in recently menopausal women, hormone therapy showed no adverse effect on early markers of atherosclerosis over 4 years.. The ELITE trial found that estrogen slowed artery thickening when started within 6 years of menopause, but not when started more than 10 years out 4Ref 4Hodis HN, Mack WJ, Henderson VW, et al. (2016).Vascular effects of early versus late postmenopausal treatment with estradiol.ELITE trial: estradiol slowed carotid artery-wall thickening when started within 6 years of menopause but not when started 10 or more years after.. Starting after age 60, or more than a decade past menopause, shifts the balance toward more caution 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.2022 NAMS position statement: good candidates are typically healthy women under 60 or within 10 years of menopause; contraindications include estrogen-sensitive cancers, clots, stroke, heart attack, unexplained bleeding, and active liver disease; transdermal routes lower clot risk; duration is individualized with no single mandatory stopping point.. This is why a clinician asks not just your age but how long ago your periods stopped.

Who has real reasons to avoid systemic HRT?

Some conditions are genuine reasons to avoid systemic estrogen, and the list is shorter than many people expect. The main ones include:

• A personal history of breast cancer or another estrogen-sensitive cancer
• A history of blood clots, stroke, or heart attack
• Unexplained vaginal bleeding until it has been evaluated
• Active liver disease

According to The North American Menopause Society, these are the principal contraindications to systemic therapy, and having one does not always rule out low-dose vaginal estrogen for local symptoms 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.2022 NAMS position statement: good candidates are typically healthy women under 60 or within 10 years of menopause; contraindications include estrogen-sensitive cancers, clots, stroke, heart attack, unexplained bleeding, and active liver disease; transdermal routes lower clot risk; duration is individualized with no single mandatory stopping point.5Ref 5The North American Menopause Society (Menopause Society) (2023).The 2023 nonhormone therapy position statement of The North American Menopause Society.2023 NAMS nonhormone position statement: non-hormonal medicines and behavioral approaches can reduce vasomotor symptoms for those who avoid systemic estrogen.. A family history alone is usually weighed, not disqualifying, and a clinician can help gauge how much a given history matters.

What are the options if you have risk factors?

Having a risk factor does not always mean going without relief, because several alternatives exist. For women who cannot or prefer not to use systemic estrogen, non-hormonal medicines and behavioral approaches can reduce hot flashes 5Ref 5The North American Menopause Society (Menopause Society) (2023).The 2023 nonhormone therapy position statement of The North American Menopause Society.2023 NAMS nonhormone position statement: non-hormonal medicines and behavioral approaches can reduce vasomotor symptoms for those who avoid systemic estrogen.. According to The North American Menopause Society, transdermal estrogen appears to carry a lower clot risk than oral estrogen, which can matter for some candidates 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.2022 NAMS position statement: good candidates are typically healthy women under 60 or within 10 years of menopause; contraindications include estrogen-sensitive cancers, clots, stroke, heart attack, unexplained bleeding, and active liver disease; transdermal routes lower clot risk; duration is individualized with no single mandatory stopping point.. There are also ways to ease hot flashes that do not involve hormones at all 5Ref 5The North American Menopause Society (Menopause Society) (2023).The 2023 nonhormone therapy position statement of The North American Menopause Society.2023 NAMS nonhormone position statement: non-hormonal medicines and behavioral approaches can reduce vasomotor symptoms for those who avoid systemic estrogen.. Women concerned about their bones can review osteoporosis risk factors with a clinician 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.2022 NAMS position statement: good candidates are typically healthy women under 60 or within 10 years of menopause; contraindications include estrogen-sensitive cancers, clots, stroke, heart attack, unexplained bleeding, and active liver disease; transdermal routes lower clot risk; duration is individualized with no single mandatory stopping point.. The point is that a risk factor usually narrows the options rather than closing every door.

When HRT candidacy needs a menopause clinician

A clinician with menopause expertise can weigh your age, timing, symptoms, and history against the short list of cautions. That personalized read is why candidacy is rarely a simple yes or no, and why a fuller look at whether HRT is safe belongs in that visit 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.2022 NAMS position statement: good candidates are typically healthy women under 60 or within 10 years of menopause; contraindications include estrogen-sensitive cancers, clots, stroke, heart attack, unexplained bleeding, and active liver disease; transdermal routes lower clot risk; duration is individualized with no single mandatory stopping point.. One persistent myth is that everyone must stop at age 60 or after 5 years, when current guidance individualizes duration instead 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.2022 NAMS position statement: good candidates are typically healthy women under 60 or within 10 years of menopause; contraindications include estrogen-sensitive cancers, clots, stroke, heart attack, unexplained bleeding, and active liver disease; transdermal routes lower clot risk; duration is individualized with no single mandatory stopping point.. According to The North American Menopause Society, there is no single mandatory stopping point 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.2022 NAMS position statement: good candidates are typically healthy women under 60 or within 10 years of menopause; contraindications include estrogen-sensitive cancers, clots, stroke, heart attack, unexplained bleeding, and active liver disease; transdermal routes lower clot risk; duration is individualized with no single mandatory stopping point.. Reviewing benefits and risks together, then revisiting the plan periodically, keeps the decision matched to your health over time. Gale can help you prepare for that conversation.